Foligest75IU/vial

• Ovulation Induction in Women: in patients who have previously received pituitary suppression.
• Multi-follicular Development: during ART cycles (controlled ovarian stimulation).
• Polycystic Ovarian Syndrome (PCOS): treatment of PCOS-related infertility.
• Male Infertility: in combination with HCG for spermatogenesis deficiency due to hypogonadotrophic-hypogonadism.

Ovulation Induction in Women:

• Starting dose: 50 IU/day for at least the first 7 days SC or IM.
• Increase by 25 or 50 IU at weekly intervals.
• When pre-ovulatory state achieved, administer HCG (5,000-10,000 IU).

ART (Women):

• Starting dose: 150-225 IU/day for at least first 4 days IM.
• Adjust dose based on ovarian response.

PCOS:

• Start with 50 IU daily (4-6 days).
• Increase to 75, 112, 150 and 225 IU if needed.

Male Spermatogenesis:

• Pre-treatment with HCG (1,500 IU twice weekly).
• When serum testosterone normalised, FSH 450 IU/week (2-3 times weekly) with HCG.

* Use as directed by the registered physician

Common Side Effects:

• Headache
• Vaginal bleeding
• Nausea
• Hot flashes
• Injection site reaction (bruising, pain, redness)
• Pelvic pain
• Ovarian hyperstimulation
• Breathing problems

Serious Side Effects: Ovarian hyperstimulation syndrome (OHSS), blood clots, stroke, ectopic pregnancy, multiple births.

Precautions:

• Exclude uncontrolled non-gonadal endocrinopathies (thyroid, adrenal or pituitary disorders).
• Increased risk of multiple gestations.
• Ovarian hyperstimulation (OHSS) - requires ultrasound and estradiol monitoring.
• Increased risk of ectopic pregnancy - early ultrasound confirmation important.
• In men, semen analysis is recommended 4 to 6 months after beginning treatment.